Lung Cancer Clincial Trials

NSCLC – unresectable stage III

MERCK (3475-799)

A Phase II Trial of Pembrolizumab in Combination with Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (KEYNOTE-799)

Learn more.


NSCLC – resectable  stage IIB-IIIA (neoadjuvant/ adjuvant)

MERCK (3475-671)

A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer

Learn more.


NSCLC Stage IV 1st line

MERCK (7902-007)

A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)

Learn more.


NSCLC (Adjuvant) large 1B (≥4cm), II or IIIA.

A151216 (ALCHEMIST)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). Testing for EGFR, ALK, PD-L1. Sponsor will pay for testing if no local results available.

Learn more.


NSCLC (Adjuvant-Adenocarcinoma)

A081105 (Sub-study of Alchemist)

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Learn more.


NSCLC (Adjuvant-Adenocarcinoma)

E4512 (Sub-study of Alchemist)

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Learn more.


NSCLC (Adjuvant-Squamous or non-squamous EGFR/ALK wild type)

EA5142 (Sub-study of Alchemist)

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers.

Learn more.


NSCLC Stage IV 2nd line (LUNG-MAP)

LungMap

A Biomarker-Driven Master Protocol for Previously Treated Non-Small Cell Lung Cancer (LUNG-MAP)

Learn more.


NSCLC Squamous Only Stage IV 2nd line (LUNG-MAP)

A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD1 resistant Stage IV non-small cell lung cancer.

Learn more.


SCLC (limited & extensive)

CC003

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Learn more.

Need assistance?

Contact us